Transcription factor LSF (TFCP2) inhibits melanoma growth

Yuji Goto; Ichiro Yajima; Mayuko Kumasaka; Nobutaka Ohgami; Asami Tanaka; Toyonori Tsuzuki; Yuji Inoue; Satoshi Fukushima; Hironobu Ihn; Mikiko Kyoya; Hiroyuki Ohashi; Tamihiro Kawakami; Dorothy C. Bennett; Masashi Kato

doi:10.18632/oncotarget.6230

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Transcription factor LSF (TFCP2) inhibits melanoma growth

Yuji Goto, Ichiro Yajima, Mayuko Kumasaka, Nobutaka Ohgami, Asami Tanaka, Toyonori Tsuzuki, Yuji Inoue, Satoshi Fukushima, Hironobu Ihn, Mikiko Kyoya, Hiroyuki Ohashi, Tamihiro Kawakami, Dorothy C. Bennett and Masashi Kato _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:2379-2390. https://doi.org/10.18632/oncotarget.6230

Metrics: PDF 1955 views | HTML 3167 views | ?

Abstract

Yuji Goto1,2, Ichiro Yajima1,3, Mayuko Kumasaka1,3, Nobutaka Ohgami1,3, Asami Tanaka1, Toyonori Tsuzuki4, Yuji Inoue5, Satoshi Fukushima5, Hironobu Ihn5, Mikiko Kyoya6, Hiroyuki Ohashi6, Tamihiro Kawakami6, Dorothy C. Bennett7 and Masashi Kato1,3

1 Department of Biomedical Sciences, College of Life and Health Sciences, Chubu University, Matsumoto-cho, Kasugai-shi, Aichi, Japan

2 Department of Biology, Faculty of Science, Toho University, Miyama, Funabashi, Japan

3 Department of Occupational and Environmental Health, Nagoya University Graduate School of Medicine, Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan

4 Department of Pathology, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan

5 Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

6 Department of Dermatology, St. Marianna University School of Medicine, Sugao, Miyamae-ku, Kawasaki, Kanagawa, Japan

7 Molecular Cell Sciences Research Centre, St George’s, University of London, London, UK

Correspondence to:

Masashi Kato, email:

Keywords: melanoma, transcription factor LSF, TFCP2, CDKN1A, cell cycle

Received: May 28, 2015 Accepted: October 09, 2015 Published: October 25, 2015

Abstract

Late SV40 factor 3 (LSF), a transcription factor, contributes to human hepatocellular carcinoma (HCC). However, decreased expression level of LSF in skin melanoma compared to that in benign melanocytic tumors and nevi in mice and humans was found in this study. Anchorage-dependent and -independent growth of melanoma cells was suppressed by LSF overexpression through an increased percentage of G1 phase cells and an increased p21CIP1 expression level in vitro and in vivo. Anchorage-dependent growth in LSF-overexpressed melanoma cells was promoted by depletion of LSF in the LSF-overexpressed cells. Integrated results of our EMSA and chromatin immunoprecipitation assays showed binding of LSF within a 150-bp upstream region of the transcription start site of p21CIP1 in melanoma cells. Taken together, our results suggest potential roles of LSF as a growth regulator through control of the transcription of p21CIP1 in melanocytes and melanoma cells as well as a biomarker for nevus.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6230

Publication Alerts

Research Papers:

Transcription factor LSF (TFCP2) inhibits melanoma growth

Abstract